NCT02014337 - Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Breast CancerOvarian Epithelial Cancer RecurrentSarcomaNon-small Cell Lung CancerCarcinoma, Transitional CellProstate CancerProstatic Neoplasms

Interventions

DRUG

Mifepristone and Eribulin in combination

Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients

Trial Locations (11)

22031

Virginia Cancer Specialists, Fairfax

30308

Winship Cancer Institute, Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

48073

Quest Research, Royal Oaks

60637

Rita Nanda, MD, Chicago

64111

St. Luke's Cancer Institute, Kansas City

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology - Tyler, Tyler

78217

Cancer Care Centers of South Texas, San Antonio

85715

ACRC/Arizona Clinical Research Center Inc., Tucson

89169

Comprehensive Cancer Centers of Nevada, Las Vegas